| Literature DB >> 31991867 |
Sander De Bruyne1, Jonas Himpe1, Sigurd E Delanghe2, Griet Glorieux2, Wim Van Biesen2, Marc L De Buyzere3, Marijn M Speeckaert2,4, Joris R Delanghe1.
Abstract
Carbamoylation is an important risk factor for accelerated atherogenesis and mortality in patients undergoing hemodialysis (HD). We intended to explore whether carbamoylation as assessed by near-infrared (NIR) analysis of nail proteins is associated with (a) serum concentrations of representative uremic toxins and (b) mortality in HD patients. A total of 53 healthy volunteers and 84 consecutive HD patients were enrolled in this cross-sectional cohort study. Standard laboratory methods were used to measure routine parameters, whereas levels of uremic toxins were determined using reversed-phase high-performance liquid chromatography (RP-HPLC). Spectra of distal fingernail clippings were obtained using an Avantes NIR spectrometer and processed using chemometric data analysis. The second derivative of the peak intensity at 1494 nm attributed to N-H amide bands from NH2 of carbamoyl (-CONH2) groups was higher in HD patients than in control subjects (p < 0.0001). Peak intensity levels were associated with age and plasma levels of representative uremic toxins. Cox-regression analysis revealed a significant association with all-cause mortality, even after adjustment for age. In conclusion, our data revealed that carbamoylation as assessed by NIR analysis of nail proteins is associated with serum concentrations of uremic toxins and also with mortality in HD patients. Further research to explore whether it is a surrogate marker or a hard indicator of mortality risk is warranted.Entities:
Keywords: carbamoylation; hemodialysis; keratins; mortality; nails; near-infrared spectroscopy; uremia; uremic toxins
Mesh:
Substances:
Year: 2020 PMID: 31991867 PMCID: PMC7076796 DOI: 10.3390/toxins12020083
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Carbamoylation is a nonenzymatic and irreversible post-translational modification during which a carbamoyl group (-CONH2) is added to proteins, peptides and amino acids by reaction with isocyanic acid, resulting in the formation of an irreversible covalent bond. Isocyanic acid originates mainly (1) from the spontaneous decompostion of urea into ammonium and cyanate, a reactive ion that is quickly converted to isocyanic acid, or (2) from myeloperoxidase (MPO)-catalyzed oxidation of thiocyanate at sites of inflammation, including atherosclerotic plaques, or (3) from environmental factors [2,10]. In chronic kidney disease, urea accumulates and elevates the concentration of isocyanic acid. The latter rapidly reacts with the α-amino group of peptides, proteins (e.g., nail keratins) or amino acids and with the ε-amino group of lysine, which results in the formation of homocitrulline (ε-amino-carbamoyl-lysine) [2].
Demographic, clinical and laboratory measurements in healthy subjects and HD patients.
| Variable | Control ( | HD ( |
|---|---|---|
|
| ||
| Age (yr) | 34.8 (27.5–43.5) | 73.7 (62.0–81.3) |
| Male/female ratio | 18/35 | 52/32 |
| Caucasian (%) | 100 | 100 |
| History of CVD (%) | 0 | 59.5 |
| Diabetes mellitus (%) | 0 | 35.7 |
| BMI (kg/m2) | 23.2 (20.6–25.7) | 26.1 (23.4–29.1) |
|
| ||
| Creatinine (mg/dL) | 0.9 (0.8–1.0) | 7.0 (5.0–8.8) |
| CRP (mg/L) | 1.1 (0.7–2.8) | 4.7 (1.9–10.8) |
| Total protein (g/L) | 74.0 (69.9–81.5) | 66.0 (62.5–69.6) |
| Urea (mg/dL) | 26.7 (22.8–31.7) | 99.0 (74.5–127.0) |
| IS total (mg/dL) | 0.06 (0.04–0.08) | 1.8 (1.0–2.6) |
| IS free (mg/dL) | 0.001 (0.0005–0.001) | 0.09 (0.05–0.2) |
| PCS total (mg/dL) | 0.2 (0.1–0.3) | 3.2 (2.0–4.2) |
| PCS free (mg/dL) | 0.008 (0.003–0.01) | 0.2 (0.1–0.3) |
| PCG total (mg/dL) | 0.001 (0.001–0.001) | 0.2 (0.1–0.4) |
| PCG free (mg/dL) | 0.001 (0.001–0.001) | 0.2 (0.08–0.4) |
| IAA total (mg/dL) | 0.03 (0.02–0.03) | 0.1 (0.1–0.2) |
| IAA free (mg/dL) | 0.001 (0.001–0.002) | 0.04 (0.03–0.06) |
| CMPF (mg/dL) | 0.05 (0.01–0.1) | 0.5 (0.3–0.9) |
| HA total (mg/dL) | 0.07 (0.05–0.1) | 2.7 (1.0–4.7) |
| HA free (mg/dL) | 0.02 (0.006–0.04) | 1.1 (0.5–2.6) |
| UA (mg/dL) | 4.1 (3.4–5.3) | 5.4 (4.8–6.4) |
Abbreviations: BMI, body mass index; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid; CRP, C-reactive protein; CVD, cardiovascular disease; HD, hemodialysis; HA, hippuric acid; IAA, indole acetic acid; IS, indoxyl sulfate; PCG, p-cresylglucuronide; PCS, p-cresylsulfate; UA, uric acid; Yr, year. Data are presented as median (interquartile range).
Figure 2Spectral signature of carbamoylation. (A) Second derivative spectra of L-lysine (green line) and L-homocitrulline (blue line) powder. Characteristic spectral peaks are indicated. (B) Second derivative of the median spectra from controls (n = 53, green line) and hemodialysis patients (n = 84, blue line). Concordant spectral changes with the differences observed in the spectra of lysine and homocitrulline are highlighted (1494 nm region in red).
Overview of the characteristic spectral peaks observed in the spectrum of homocitrulline with associated functional groups, differences with the spectrum of lysine, concordance with spectral changes observed in controls (n = 53) and hemodialysis (HD, n = 84) patients and influence of diabetes mellitus (DM).
| Wavelength (nm) | Associated Functional Groups | Homocit vs. lys | Control (Intensity) | HD (Intensity) |
| In Line | Sign. Influence DM ( |
|---|---|---|---|---|---|---|---|
| 1390 | C-H bands | increase | −0.012 | −0.011 | <0.0001 | yes | No (0.24) |
| 1468 | CONH2 (N-H combination band) | decrease | −0.0044 | −0.0062 | <0.0001 | yes | No (0.42) |
| 1494 | N-H amide | increase | 0.012 | 0.014 | <0.0001 | yes | No (0.90) |
| 1532 | N-H amide | decrease | 0.0097 | 0.0090 | 0.0001 | yes | Nearly sign. decrease (0.069) |
| 1571 | N-H amide | increase | 0.00034 | −0.000043 | 0.0001 | no | No (0.72) |
| 1610 | C=O/N-H combination | increase | −0.00032 | −0.0011 | <0.0001 | no | No (0.91) |
| 1655 | C-H methyl | increase | −0.024 | −0.026 | 0.0006 | no | Nearly sign. increase (0.073) |
| 1693 | CONH2 (N-H and C=O) | decrease | - | - | n.s. | - | - |
| 1706 | C-H methyl | increase | −0.0016 | −0.00054 | 0.0003 | yes | No (0.80) |
| 1744 | CONH2 (C=O hydrogen bonded to N-H) | decrease | - | - | n.s. | - | - |
| 1955 | CONH2 (N-H combination band) | decrease | 0.0040 | 0.0029 | <0.0001 | yes | No (0.83) |
| 1981 | CONH2 (N-H amide II) | increase | - | - | n.s. | - | - |
| 2012 | CONH2 (N-H/C-N combination band) | - | - | - | n.s. | - | - |
| 2057 | CONH2 (N-H/C=O amide) | increase | - | - | n.s. | - | - |
| 2069 | N-H amide (N-H deformation) | decrease | - | - | n.s. | - | - |
| 2095 | N-H | increase | - | - | n.s. | - | - |
| 2146 | N-H/C-N/C=O | increase | −0.00076 | 0.00022 | <0.0001 | yes | No (0.60) |
| 2203 | CONH2 (N-H and C=O) | decrease | 0.0048 | 0.0039 | =0.010 | yes | No (0.39) |
| 2222 | N-H combination | increase | - | - | n.s. | - | - |
| 2260 | CONH2 (N-H and C=O) | decrease | - | - | n.s. | - | - |
| 2291 | CONH2 (C=O hydrogen bonded to N-H) | increase | - | - | n.s. | - | - |
Abbreviations: homocit, homocitrulline; lys, lysine; nm, nanometer; n.s., nonsignificant; sign., significant. The p-values represent the results of Mann–Whitney U tests.
Figure 3Close-up on the median second derivative spectra from controls (n = 53, green line) and hemodialysis patients (n = 84, blue line) of the eight regions, characterized by changes in line with the spectra of homocitrulline and lysine. (A) 1390 nm; (B) 1468 nm; (C) 1494 nm; (D) 1532 nm; (E) 1706 nm; (F) 1955 nm; (G) 2146 nm; and (H) 2203 nm.
Multiple regression models with the peak intensity at 1494 nm (milliunits) as a dependent variable.
| Model | r2 (p) | Retained Variables | β (SE) |
|
|---|---|---|---|---|
| Age, DM and urea | 0.24 (<0.001) | Age (yr) | 0.038 (0.0060) | <0.0001 |
| Age, DM and IS total | 0.27 (<0.001) | Age (yr) | 0.028 (0.0067) | 0.0001 |
| IS total (mg/dL) | 0.34 (0.12) | 0.0058 | ||
| Age, DM and PCG total | 0.26 (<0.001) | Age (yr) | 0.029 (0.0072) | 0.0001 |
| PCG total (mg/dL) | 1.29 (0.58) | 0.028 | ||
| Age, DM and PCG free | 0.26 (<0.001) | Age (yr) | 0.029 (0.0071) | 0.0001 |
| PCG free (mg/dL) | 1.41 (0.63) | 0.027 | ||
| Age, DM and HA total | 0.27 (<0.001) | Age (yr) | 0.029 (0.0067) | <0.0001 |
| HA total (mg/dL) | 0.14 (0.050) | 0.0063 | ||
| Age, DM and HA free | 0.26 (<0.001) | Age (yr) | 0.030 (0.21) | <0.0001 |
| HA free (mg/dL) | 0.21 (0.082) | 0.013 |
Abbrevations: DM, diabetes mellitus; HA, hippuric acid; IS, indoxyl sulfate; PCG, p-cresylglucuronide; SE, standard error; Yr, year.
Figure 4(A) Close-up on the second derivative spectra of the 1494 nm region in control subjects (n = 53, green line), hemodialysis (HD) patients who survived (n = 53, blue line) and HD patients who died during the 3-year follow-up period (n = 31, red line). (B) Box-and-whisker plots illustrating differences in peak intensities between controls, HD patients who survived and HD patients who died during the follow-up period. The p-values represent results obtained from Mann–Whitney U tests. Unadjusted (C) and age-adjusted (D) cox-regression survival curves for increasing tertiles of the spectral marker at 1494 nm in the group of hemodialysis patients (n = 84).
Unadjusted and age-adjusted Cox regression analysis for all-cause mortality with the intensity at 1494 nm (milliunits) entered as a continuous variable in all hemodialysis patients (n = 84).
| Models of Patient Survival (Events | HR | 95% CI |
|
|---|---|---|---|
|
| |||
| Intensity at 1494 nm (milliunits) | 1.81 | 1.26–2.58 | 0.0012 |
|
| |||
| Intensity at 1494 nm (milliunits) | 2.05 | 1.22–3.01 | 0.0001 |
| Age (yr) | 1.07 | 1.03–1.11 | 0.0002 |
Abbreviations: CI, confidence interval; HR, hazard ratio; yr, year.